afamelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-18. Numbers and descriptions here follow the published literature rather than marketing material.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
== History == The party was established in April 1918 in order to contest the general elections later that month. Pais was the only candidate for president, and was elected unopposed, whilst the PNR won 108 of the 155 seats in the House of Representatives and 32 of the 73 Senate seats. However, the elections were boycotted by the Democratic Party, the Evolutionist Party and the Republican Union, which had won all but 16 of the seats in the 1915 elections. After Pais was assassinated later in December 1918, the party went into decline, and merged with the Republican Liberal Party and the Reconstitution Party to form the Nationalist Republican Party in 1923.
=== Complex flavoenzymes === Glutamate synthase catalyzes the conversion of 2-oxoglutarate into L-glutamate with L-glutamine serving as the nitrogen source for the reaction. All glutamate syntheses are iron-sulfur flavoproteins containing an iron-sulfur cluster and FMN. The three classes of glutamate syntheses are categorized based on their sequences and biochemical properties. Even though there are three classes of this enzyme, it is believed that they all operate through the same mechanism, only differing by what first reduces the FMN. The enzyme produces two glutamate molecules: one by the hydrolysis of glutamine (forming glutamate and ammonia), and the second by the ammonia produced from the first reaction attacking 2-oxoglutarate, which is reduced by FMN to glutamate.
The effect of amphetamine on monoamine transporters appears to involve phosphorylation, in which activated protein kinases attach a phosphate group to a specific amino acid residue on the transporter protein. Depending on the protein kinase involved and the residue(s) phosphorylated, phosphorylation can shift transporter function into an efflux-permissive state that causes the reverse transport of cytosolic monoamines into the synaptic cleft, or it can promote transporter internalization, whereby phosphorylated transporters are withdrawn from the plasma membrane and lower total reuptake capacity (i.e., non-competitive reuptake inhibition). As of January 2026, protein kinase A (PKA), protein kinase C (PKC), Ca2+/calmodulin-dependent protein kinase II (CaMKII), and Ras homolog family member A (RhoA) have all been demonstrated experimentally to regulate monoamine transporter function activity following amphetamine exposure. Amphetamine has been identified as a full agonist of trace amine-associated receptor 1 (TAAR1), a Gs-coupled and G13-coupled G protein-coupled receptor (GPCR) discovered in 2001, which is important for regulation of brain monoamines. Several reviews have linked amphetamine's agonism at TAAR1 to modulation of monoamine transporter function and subsequent neurotransmitter efflux and reuptake inhibition at monoaminergic synapses.
== Properties == Energy plays a very important role in p3 peptides. While Aβ models have a strong negative energy, p3 oligomeric models have a positive one. Another characteristic that must be pointed out is that p3 peptides have more solvent-exposed hydrophobic surfaces (60%) than Aβ oligomers do (20%), so buried surface areas are not as big within p3 oligomers (30%) as they are within Aβ oligomers. These evidences show that the expected energy of the Aβ-based oligomeric models of p3 is always positive and that these models expose hydrophobic patches to the solvent and bury a small proportion of their accessible surface within the oligomeric intermediates. Having these facts into account, we can state that p3 oligomers' existence is thermodynamically unfavourable, which suggests that the p3 peptide cannot form stable soluble oligomers in the same way Aβ does. Solution of p3 cannot assemble into stable oligomers as Aβ1–42 in the same concentration does. Therefore, it is very possible that p3 could not last long by itself, evolving rapidly into fibrillar forms that hide exposed hydrophobic patches. p3 peptides have been analyzed in some researches with Western blot techniques. Primary antibodies were used to recognize Aβ1–16 residues. Unexpectedly, it was discovered that the residues did not show any signal. This confirms the absence of N-terminal domain Aβ1-16 in p3 peptides.
Tapentadol was invented at the German pharmaceutical company Grünenthal in the late 1980s led by Helmut Buschmann; the team started by analyzing the chemistry and activity of tramadol, which had been invented at the same company in 1962. Tramadol has several enantiomers, and each forms metabolites after processing in the liver. These tramadol variants have varying activities at the μ-opioid receptor, the norepinephrine transporter, and the serotonin transporter, and differing half-lives, with the metabolites having the best activity. Using tramadol as a starting point, the team aimed to discover a single molecule that minimized the serotonin activity, had strong μ-opioid receptor agonism and strong norepinephrine reuptake inhibition, and would not require metabolism to be active; the result was tapentadol. In 2003 Grünenthal partnered with two Johnson & Johnson subsidiaries, Johnson & Johnson Pharmaceutical Research and Development and Ortho-McNeil Pharmaceutical to develop and market tapentadol; Johnson & Johnson had exclusive rights to sell the drug in the US, Canada, and Japan while Grünenthal retained rights elsewhere. In 2008 tapentadol received approval by the US Food and Drug Administration; in 2009 it was classified by US Drug Enforcement Agency as a Schedule II drug, and entered the US market. Tapentadol was reported to be the "first new molecular entity of oral centrally acting analgesics" class approved in the United States in more than 25 years. In 2010 Grünenthal granted Johnson & Johnson the right to market tapentadol in about 80 additional countries.
Sources: en.wikipedia.org
=== Ischemic stroke === In adults diagnosed with acute ischemic stroke, thrombolytic treatment with alteplase is the standard of care. Administration of alteplase is associated with improved functional outcomes and reduced incidence of disability. Alteplase used in conjunction with mechanical thrombectomy is associated with better outcomes.
During each turn of the cycle, two carbon atoms leave the cycle as CO2 in the decarboxylation reactions catalyzed by isocitrate dehydrogenase and alpha-ketoglutarate dehydrogenase. Thus each turn of the citric acid cycle oxidizes an acetyl-CoA unit while regenerating the oxaloacetate molecule with which the acetyl-CoA had originally combined to form citric acid. The decarboxylation reactions occur before malate is formed in the cycle. Malate is the only substance that can be removed from the mitochondrion to enter the gluconeogenic pathway to form glucose or glycogen in the liver or any other tissue. There can therefore be no net conversion of fatty acids into glucose. Only plants possess the enzymes to convert acetyl-CoA into oxaloacetate from which malate can be formed to ultimately be converted to glucose.
=== Protein === C3orf52 consists of a disordered region, a transmembrane region, and a major polyA site. The molecular weight is of 24.3 kDa. This protein is predicted to be localized primarily in the cytoplasm (94.1%), with specific localization to the endoplasmic reticulum (44.4%). The protein is associated with two distinct isoforms; isoform 1 is 250 amino acids long, while isoform 2 is 217 amino acids long. In human research, isoform 2 is the predominant variation found and is the most common focus for research on C3orf52. Compositional analysis has indicated that this protein is acidic in nature, with a predicted isoelectric point of 3.99. Additionally, results show a high-scoring transmembrane segment spanning amino acids 66 to 93, which is also among the protein's most hydrophobic segment. C3orf52 contains a repetitive four-amino acid motif, including a sequence reading "LELS" at amino acids 13-16 and repeating at positions 101–104, this region is not conserved among orthologs.
Cortisone is a naturally occurring, mostly inactive pregnene (21-carbon) steroid hormone. In the body, cortisone is produced as part of the cortisol–cortisone shunt, which protects vulnerable organs like the kidneys from cortisol. These organs produce the enzyme 11β-HSD2 which locally converts cortisol into inactive cortisone. Cortisone is later converted back into the active steroid cortisol by the enzyme 11β-HSD1, particularly in the liver, which maintains blood cortisol levels. Without the reaction converting cortisol into cortisone, cortisol binds with the mineralocorticoid receptors of the kidney, causing hypertension along with the other symptoms of apparent mineralocorticoid excess syndrome. Because it gets converted into cortisol by the body, it is sometimes used as a pharmaceutical prodrug as an alternative to directly taking cortisol. The term "cortisone" is frequently misused to mean either any corticosteroid or hydrocortisone, which is in fact cortisol. Many who speak of receiving a "cortisone shot" or taking "cortisone" are more likely receiving hydrocortisone or one of many other, much more potent synthetic corticosteroids. Cortisone can be administered as a prodrug, meaning it has to be converted by the body (specifically the liver, converting it into cortisol) after administration to be effective. It is used to treat a variety of ailments and can be administered intravenously, orally, intra-articularly (into a joint), or transcutaneously. Cortisone suppresses various elements of the immune system, thus reducing inflammation and attendant pain and swelling.
Sources: en.wikipedia.org
== Limitations == Different energies in the ion source can cause variations in negative ion formation and make the mass spectra difficult to duplicate. Results shown in the mass spectrum can vary from instrument to instrument. The temperature of the ion source needs to be monitored. An increase in fragment ions occurs at higher temperatures. Lower temperatures will lower the energy of electrons. Set temperatures can vary, but it is important for electron energy to approach thermal levels for resonance electron capture to occur. Pressure of the added enhancement gas needs to be determined. Increasing the pressure will help stabilize the anions and extend the lifetimes of the negative ions. If the pressure is too high, not as many ions can exit the ion source. Analysis should be done using low sample loads for GC-EC-MS. The amount of sample will affect the ion abundance and cause variations in data.
== See also == RO5073012 – TAAR1 weak partial agonist RO5166017 – TAAR1 partial or full agonist RO5256390 – TAAR1 partial or full agonist RO5263397 – TAAR1 partial agonist EPPTB – TAAR1 antagonist/inverse agonist
Anthropodermic bibliopegy—the binding of books in human skin—peaked in the 19th century. The practice was most popular amongst doctors, who had access to cadavers in their profession. It was nonetheless a rare phenomenon even at the peak of its popularity, and fraudulent claims were commonplace; by 2020, the Anthropodermic Book Project had confirmed the existence of 18 books bound in human skin, out of 31 tested cases. The ability to unequivocally identify book bindings as being of human skin dates only to the mid-2010s. For many years, identification tended to be visual, based predominantly on the structure of pores such as hair follicles in the skin. This could be combined with evidence as circumstantial as the bindings being of subjectively poor quality—taken as a sign the skin used was acquired through suspicious means. In the early twenty-first century, DNA testing emerged as a potential means of identification, but this was confounded by human handling; items frequently touched by human hands could produce false positives, as tests would pick up on their remnants. DNA testing also proved non-viable owing to the degradation of DNA over time and the acceleration of such degradation by the tanning process used to turn skin into leather. The development of peptide mass fingerprinting permitted conclusive testing and became the gold standard method. The first book confirmed as authentic through its use was in 2014; it was a copy of Des destinées de l'ame by the French philosopher Arsène Houssaye, held in the Houghton Library of Harvard University.
==== Territories of the United States ==== Taco Bell operates several stores in Guam. Taco Bell operates one restaurant in the Northern Mariana Islands, located on the island of Saipan. In 2005 Taco Bell started the permitting process to set up a restaurant in American Samoa in Pago Pago. Taco Bell also operates stores in Puerto Rico.
Computational neurogenetic modeling is concerned with the development of dynamic neuronal models for modeling brain functions with respect to genes and dynamic interactions between genes, on the cellular level (Computational Neurogenetic Modeling (CNGM) can also be used to model neural systems).
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.